Clinical trials
Cytokine Release Syndrome trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 24 |
| 2021 | 7 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Terminated | 12 |
| Recruiting | 9 |
| Withdrawn | 6 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Corporation | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Novartis Pharmaceuticals | 2 |
| UNC Lineberger Comprehensive Cancer Center | 2 |
| University of Alabama at Birmingham | 2 |
| University of Minnesota | 2 |
| Ashvattha Therapeutics, Inc. | 1 |
| Boston Medical Center | 1 |
| CHRISTUS Health | 1 |
| Children's Hospital of Philadelphia | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cytokine Release Syndrome | 48 |
| COVID-19 | 25 |
| Coronavirus Infections | 7 |
| Respiratory Distress Syndrome | 7 |
| Multiple Myeloma | 6 |
| Pneumonia | 6 |
| Inflammation | 4 |
| Lymphoma | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Lymphohistiocytosis, Hemophagocytic | 3 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.